Therapy and Cytogenetic Complexity Shape the Mir-335/Sox4 Axis in Multiple Myeloma
Background Multiple myeloma (MM) is characterized by marked biological and genomic heterogeneity that may influence the activity of post-transcriptional regulatory networks. We previously identified SOX4 as a contributor to MM progression. Here, we investigated the functional activity of its post-transcriptional regulator miR-335 in primary patient-derived plasma cells and assessed whether disease stage, baseline SOX4 expression, and cytogenetic background influence miR-335 responsiveness. Methods Primary CD138 + plasma cells were isolated from bone marrow aspirates of 93 patients with MGUS/SMM (n = 11), newly diagnosed MM (ND-MM; n = 29), or treated MM (T-MM; n = 53). Each sample was divided into matched Sham-control and miR-335-transfected fractions. SOX4 modulation was evaluated by RT-qPCR and confirmed at protein level in representative samples. Responses were analyzed according to baseline SOX4 and CD56 expression, ploidy, and chromosome 1q status. miR-335 activity was independently assessed through SOX4/SPP1 concordance in 45 samples, while functional and morphological effects were evaluated in primary MM cultures. Results Baseline SOX4 expression increased with disease progression and was highest in T-MM. miR-335 significantly reduced SOX4 expression in T-MM, with the strongest response in samples with high baseline SOX4 expression (median miR-335/Sham ratio 0.47 versus 0.90 in SOX4-low T-MM; p < 0.01). SOX4 and SPP1 modulation were strongly concordant in the validation cohort (R²=0.74), while ACTB remained stable. Responsiveness was associated with CD56 expression and cytogenetic background: T-MM CD56-positive samples showed greater SOX4 suppression than CD56-negative samples, while euploid and chromosome 1q non-amplified T-MM cases were more responsive than their respective counterparts. miR-335 also reduced residual cell numbers in both ND-MM and T-MM cultures (p < 0.01). Notably, therapy-conditioned cells developed rosette-like multicellular aggregates following miR-335 exposure, suggesting a distinct adaptive phenotype associated with altered adhesion and microenvironment-related signaling. Conclusions miR-335 responsiveness in primary MM cells is shaped by disease stage, baseline SOX4 expression, cellular phenotype, and cytogenetic background. These findings identify a functionally responsive, therapy-conditioned MM subset and support a patient-stratified framework for investigating miR-335-based therapeutic strategies.
Authors
- Barbara Montante (ORCID: https://orcid.org/0000-0002-8780-7557)
- Elisabetta Lombardi (ORCID: https://orcid.org/0000-0002-3688-9281)
- Chiara Cigana
- Roberto Vettori
- Rosanna Ciancia (ORCID: https://orcid.org/0000-0002-2364-4920)
- Mario Mazzucato (ORCID: https://orcid.org/0000-0001-8319-053X)
- Mariagrazia Michieli (ORCID: https://orcid.org/0000-0001-6302-0488)
- Maurizio Zanetti (ORCID: https://orcid.org/0000-0001-6346-8776)
- Marco Valvasori
- Silvia Crestani
- Francesco Agostini (ORCID: https://orcid.org/0000-0002-2808-9348)
- Maurizio Rupolo (ORCID: https://orcid.org/0000-0001-7932-2827)
- Kevin Rossi (ORCID: https://orcid.org/0000-0001-8428-5127)
- Gonzalo Almanza (ORCID: https://orcid.org/0009-0004-7204-6777)
- Riccardo Mezzetti
- Joanna Dorota Barchanowska
- Iris Scapinello
- Matteo Valoppi
Institutions
- University of California San Diego (US)
- Centro di Riferimento Oncologico (IT)
- Moores Cancer Center (US)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-18
- DOI
- https://doi.org/10.21203/rs.3.rs-11139074/v1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- preprint